RespireRx Pharmaceuticals Inc (RSPI)

[NeutrinoKid]

The specific competence that the Australian subsidiary brings to RespireRx is access to the manufacturing and testing of the lipid nanoparticule in situ drug delivery formulation. This is done in collaboration with a third party located also in Australia, Ab Initio.

Dronabinol is, if you want, incidental. The purpose is to harness the nanoparticles, which can be used with other compounds. Note that the particular challenge that the Ampakines drugs faced was effective delivery, since high potency versions had unacceptable side effects, while the gentler low potency drugs tended to not get to the target tissue in adequate amounts or timing. Such that the nanoparticles can rehabilitate the Ampakine pipeline. And the same holds for the GABAkines, i.e. KRM-II-81, and analogs.

“ the ability of KRM-II-81 to dramatically reduce epileptiform electrical activity when administered in situ.”

https://ab-initio-pharma.com/news/2023/10/13/ab-initio-signs-master-service-agreement-with-resolution-rx